What is Ultragenyx (RARE) stock price today?

Ultragenyx (RARE) currently trades at $26.12 per share. The stock has a market capitalization of $2.57B and a P/E ratio of —x.

Is RARE stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Ultragenyx has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -3.91.

What is Ultragenyx's revenue and earnings?

Ultragenyx has trailing twelve-month (TTM) revenue of $670.00M with profit margins of -90.90%. Earnings per share (EPS) is $-6.10.

Is Ultragenyx financially healthy?

Ultragenyx's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -3.91 places it in the distress.

RARE

Ultragenyx

NASDAQ: RARE · HEALTHCARE · BIOTECHNOLOGY

$26.12

-0.04% today

Updated 2026-05-08

Market cap

$2.57B

P/E ratio

—

P/S ratio

3.84x

EPS (TTM)

$-6.10

Dividend yield

—

52W range

$18 – $42

Volume

2.0M

Market cap

$2.57B

P/E ratio

—

P/S ratio

3.84x

EPS (TTM)

$-6.10

Dividend yield

—

52W range

$18 – $42

Volume

2.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

4.3

Quality

2.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-3.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →195 stocks currently score above 75

Price targets

Analyst target

$53.20

+103.68%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

5 Strong Buy13 Buy2 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -3.91 — distress zone

- Thin margins at -90.90%

- Negative free cash flow $-100.77M

- Revenue declining -2.40% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$363.33M	$434.25M	$560.23M	$673.00M	$670.00M
Net income	$-707.42M	$-606.64M	$-569.18M	$-575.00M	$-129.00M
EPS	—	—	—	—	$-6.10
Free cash flow	$-526.59M	$-521.57M	$-421.68M	$-472.00M	$-100.77M
Profit margin	-194.71%	-139.70%	-101.60%	-85.44%	-90.90%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RARE	$2.57B	25	5.3	2.0	5.0	4.3	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-38.45%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-20.52%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+42.20%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Ultragenyx trades at $26.12. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -3.91, it sits in the distress. TTM revenue stands at $670.00M. with profit margins at -90.90%.

Frequently asked questions

What is Ultragenyx's stock price?

Ultragenyx (RARE) trades at $26.12.

Is Ultragenyx overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Ultragenyx (RARE)?

The analyst target price is $53.20, representing +103.7% upside from the current price of $26.12.

What is Ultragenyx's revenue?

TTM revenue is $670.00M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-3.91 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio3.84x

ROE-608.00%

Beta0.39

50D MA$22.77

200D MA$27.70

Shares out0.10B

Float0.09B

Short ratio—

Avg volume2.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

RARE vs LLY →RARE vs JNJ →RARE vs ABBV →Stock screener →